Circulating biomarkers of airflow limitation across the life span.
Where this comes from
- Record sourced from PubMed, PMID 38253260.
- Also identified by DOI 10.1016/j.jaci.2023.12.026 and PMC identifier 11162345.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Airflow limitation is a hallmark of chronic obstructive pulmonary disease, which can develop through different lung function trajectories across the life span. There is a need for longitudinal studies aimed at identifying circulating biomarkers of airflow limitation across different stages of life. This study sought to identify a signature of serum proteins associated with airflow limitation and evaluate their relation to lung function longitudinally in adults and children. This study used data from 3 adult cohorts (TESAOD [Tucson Epidemiological Study of Airway Obstructive Disease], SAPALDIA [Swiss Cohort Study on Air Pollution and Lung and Heart Diseases in Adults], LSC [Lovelace Smoker Cohort]) and 1 birth cohort (TCRS [Tucson Children's Respiratory Study]) (N = 1940). In TESAOD, among 46 circulating proteins, we identified those associated with FEV<sub>1</sub>/forced vital capacity (FVC) percent (%) predicted levels and generated a score based on the sum of their z-scores. Cross-sectional analyses were used to test the score for association with concomitant lung function. Longitudinal analyses were used to test the score for association with subsequent lung function growth in childhood and decline in adult life. After false discovery rate adjustment, serum levels of 5 proteins (HP, carcinoembryonic antigen, ICAM1, CRP, TIMP1) were associated with percent predicted levels of FEV<sub>1</sub>/FVC and FEV<sub>1</sub> in TESAOD. In cross-sectional multivariate analyses the 5-biomarker score was associated with FEV<sub>1</sub> % predicted in all adult cohorts (meta-analyzed FEV<sub>1</sub> decrease for 1-SD score increase: -2.9%; 95% CI: -3.9%, -1.9%; P = 2.4 × 10<sup>-16</sup>). In multivariate longitudinal analyses, the biomarker score at 6 years of age was inversely associated with FEV<sub>1</sub> and FEV<sub>1</sub>/FVC levels attained by young adult life (P = .02 and .005, respectively). In adults, persistently high levels of the biomarker score were associated with subsequent accelerated decline of FEV<sub>1</sub> and FEV<sub>1</sub>/FVC (P = .01 and .001). A signature of 5 circulating biomarkers of airflow limitation was associated with both impaired lung function growth in childhood and accelerated lung function decline in adult life, indicating that these proteins may be involved in multiple lung function trajectories leading to chronic obstructive pulmonary disease.
Medical subject headings
- Biomarkers
- Pulmonary Disease, Chronic Obstructive